Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.67
SQNM's Cash to Debt is ranked higher than
52% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. SQNM: 0.67 )
SQNM' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 0.67

Equity to Asset -0.19
SQNM's Equity to Asset is ranked lower than
52% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SQNM: -0.19 )
SQNM' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.87
Current: -0.19

-0.32
0.87
F-Score: 5
Z-Score: -6.16
M-Score: -0.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -22.12
SQNM's Operating margin (%) is ranked higher than
79% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. SQNM: -22.12 )
SQNM' s 10-Year Operating margin (%) Range
Min: -11450   Max: -24.12
Current: -22.12

-11450
-24.12
Net-margin (%) 0.63
SQNM's Net-margin (%) is ranked higher than
83% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SQNM: 0.63 )
SQNM' s 10-Year Net-margin (%) Range
Min: -10900   Max: 0.67
Current: 0.63

-10900
0.67
ROA (%) 0.73
SQNM's ROA (%) is ranked higher than
86% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. SQNM: 0.73 )
SQNM' s 10-Year ROA (%) Range
Min: -92.63   Max: 0.66
Current: 0.73

-92.63
0.66
ROC (Joel Greenblatt) (%) -180.07
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. SQNM: -180.07 )
SQNM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -897.73   Max: -184.03
Current: -180.07

-897.73
-184.03
Revenue Growth (3Y)(%) 32.40
SQNM's Revenue Growth (3Y)(%) is ranked higher than
92% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. SQNM: 32.40 )
SQNM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -20.6   Max: 293.1
Current: 32.4

-20.6
293.1
EBITDA Growth (3Y)(%) -75.40
SQNM's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. SQNM: -75.40 )
SQNM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.4   Max: 45.7
Current: -75.4

-75.4
45.7
EPS Growth (3Y)(%) -45.70
SQNM's EPS Growth (3Y)(%) is ranked higher than
55% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. SQNM: -45.70 )
SQNM' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.3   Max: 43.7
Current: -45.7

-59.3
43.7
» SQNM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SQNM Guru Trades in Q4 2013

Steven Cohen Sold Out
Chuck Royce Sold Out
» More
Q1 2014

SQNM Guru Trades in Q1 2014

Jim Simons 693,351 sh (New)
» More
Q2 2014

SQNM Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q4 2014

SQNM Guru Trades in Q4 2014

Jim Simons 34,240 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 282.20
SQNM's P/E(ttm) is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: 282.20 )
SQNM' s 10-Year P/E(ttm) Range
Min: 217.5   Max: 288.6
Current: 282.2

217.5
288.6
Forward P/E 47.62
SQNM's Forward P/E is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: 47.62 )
N/A
P/S 3.48
SQNM's P/S is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. SQNM: 3.48 )
SQNM' s 10-Year P/S Range
Min: 0.99   Max: 29.2
Current: 3.48

0.99
29.2
Current Ratio 2.17
SQNM's Current Ratio is ranked higher than
59% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SQNM: 2.17 )
SQNM' s 10-Year Current Ratio Range
Min: 1.52   Max: 10.63
Current: 2.17

1.52
10.63
Quick Ratio 2.06
SQNM's Quick Ratio is ranked higher than
61% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SQNM: 2.06 )
SQNM' s 10-Year Quick Ratio Range
Min: 1.12   Max: 10.63
Current: 2.06

1.12
10.63
Days Inventory 35.43
SQNM's Days Inventory is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SQNM: 35.43 )
SQNM' s 10-Year Days Inventory Range
Min: 19.21   Max: 271.27
Current: 35.43

19.21
271.27
Days Sales Outstanding 20.73
SQNM's Days Sales Outstanding is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. SQNM: 20.73 )
SQNM' s 10-Year Days Sales Outstanding Range
Min: 7.79   Max: 182.5
Current: 20.73

7.79
182.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.70
SQNM's Price/Median PS Value is ranked higher than
93% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SQNM: 0.70 )
SQNM' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 8.49
Current: 0.7

0.29
8.49
Earnings Yield (Greenblatt) -6.50
SQNM's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. SQNM: -6.50 )
SQNM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.3   Max: 6889
Current: -6.5

-10.3
6889

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QNMA.Germany,
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 
3.31 Mar 12 2013 
Weekly CFO Buys Highlight: PTSX, MTG, IRDM, SQNM, FNFG, LF Aug 13 2012 
Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares Aug 03 2012 
Sequenom Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sequenom Inc. Reports Operating Results (10-Q) May 07 2010 
Sequenom Inc. Reports Operating Results (10-Q) Aug 06 2009 


More From Other Websites
Sequenom Announces 2015 First Quarter Results Conference Call Apr 22 2015
Sequenom Announces 2015 First Quarter Results Conference Call Apr 22 2015
Sequenom (SQNM) Looks Good: Stock Gains 6.3% in Session - Tale of the Tape Apr 14 2015
Why Sequenom (SQNM) Isn't Done Growing Earnings Yet - Tale of the Tape Apr 14 2015
Sequenom is rising like a Phoenix Apr 08 2015
Fetal DNA tests prove highly accurate but experts warn of exceptions Apr 01 2015
Sequenom Laboratories To Present At ACMG Meeting Mar 24 2015
Sequenom Laboratories To Present At ACMG Meeting Mar 24 2015
Sequenom Laboratories Launches The HerediT® UNIVERSAL Test In Collaboration With Recombine Mar 19 2015
Sequenom Laboratories Launches The HerediT® UNIVERSAL Test In Collaboration With Recombine Mar 19 2015
SEQUENOM INC Financials Mar 17 2015
Kenneth Buechler Elected Chairman of Sequenom Board of Directors Mar 17 2015
Kenneth Buechler Elected Chairman of Sequenom Board of Directors Mar 17 2015
SEQUENOM INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 16 2015
SEQUENOM INC Files SEC form 10-K, Annual Report Mar 10 2015
Sequenom tops 4Q profit forecasts Mar 04 2015
Sequenom tops 4Q profit forecasts Mar 04 2015
Sequenom Reports 2014 Final And Fourth Quarter Financials Mar 04 2015
Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2014 Financial Results And Conference... Mar 04 2015
SEQUENOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK